Embed Size (px)
Citation preview
Organized by ReSViNET 4th RESVINET CONFERENCE ON RSV THERAPEUTICS
RSV Vaccines for the World
November 29th – December 1st 2017Málaga, Spain
ORGANIZING COMMITTEE
Chair – Janet EnglundChildren's Hospital & Medical Center, Seattle, United States
Chair – Asuncion Mejias The Research Institute At Nationwide Children's Hospital, Columbus, Ohio, United States
Leyla Kragten-TabatabaieJulius Clinical, Zeist & University Medical Center Utrecht, Utrecht, The Netherlands
Louis BontWilhelmina Children’s Hospital University Medical Center Utrecht, Utrecht, The Netherlands
Tessa KliestJulius Clinical, Zeist, The Netherlands
Natalie MazurWilhelmina Children’s Hospital University Medical Center Utrecht, Utrecht, The Netherlands
SCIENTIFIC ADVISORY COMMITTEERuth KarronJohns Hopkins Bloomberg School of Public Health, Baltimore, United States
Louis BontWilhelmina Children’s Hospital University Medical Center Utrecht, Utrecht, The Netherlands
Helen ChuUniversity Of Washington, Washington, United States
Janet EnglundChildren's Hospital & Medical Center, Seattle, United States
Ann FalseyUniversity Of Rochester Medical Center, New York, United States
Barney GrahamViral Pathogensis Laboratory And Translational Science Core & National Institute Of Allergy And Infectious Diseases, Bethesda, United States
Deborah HigginsRSV Vaccine Project at Path, Seattle, Washington, United States
Leyla Kragten-TabatabaieJulius Clinical, Zeist & University Medical Center Utrecht, Utrecht, The Netherlands
Asuncion Mejias The Research Institute At Nationwide Children's Hospital, Columbus, Ohio, United States
Harish NairUsher Institute Of Population Health Sciences &Informatics & The University Of Edinburgh Medical School, Edinburgh, United Kingdom
Marta NunesUniversity Of Witwatersrand, Johannesburg, South Africa & Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
Peter OpenshawFaculty Of Medicine, National Heart & Lung Institute, Imperical College London, London, United Kingdom
Pedro A. PiedraBaylor College Of Medicine, Texas, United States
PROGRAM | DAY 1 WEDNESDAY 29 NOVEMBER
10:00 – 13.0013:30 – 14.3014:30 – 15.30
ReSViNET Board Meeting (AC Hotel)Face-to-face Meeting with ReSViNET Board members Face-to-face Meeting with ReSViNET Board members
12:00 Registration and badge retrieval at Albeniz Cinema
15:45 – 16:0016:00 – 16:1516:15 – 16:45
Welcome by ReSViNET (Louis Bont & Leyla Kragten) Opening by meeting chairs (Asuncion Mejias & Janet Englund)Keynote Lecture: RSV F structural biology for beginners: antigenic sites and epitopes (Jason McLellan)
Session I RSV BURDEN AND INFANT MORTALITY
16:45 – 17:00
17:00 – 17:2017:20 – 17:4017:40 – 18:0018:00 – 18:2018:20 – 18:30
Session introduction, identifying gaps and aims of session (Chair: Fernando Polack/VaseeMoorthy) RSV Burden: Global mortality (Harish Nair)The burden of RSV community mortality in India (Ashish Satav)The burden of RSV community mortality and how to tackle it (Fernando Polack)Perspective on WHO’s priorities on RSV prevention and data for policy (Joachim Hombach)General round table discussion
18:30 – 19:30 YOUNG RESEARCHERS TOURNAMENT (4 selected short presentations by young researchers)
20:00 Welcome Drinks and Tapas (Picasso Museum)
Session II VIRUS STRUCTURE AND VACCINE DESIGN
08:30 – 08:45 08:45 – 09:1509:15 – 09:45 09:45 – 10:15 10:15 – 10:45
Session introduction, identifying gaps and aims of session (Chair: Barney Graham/Ruth Karron)Viral Fusion Proteins: Structure-Guided Vaccine Antigen Design (Barney Graham)Progress in the Development of Live Attenuated RSV Vaccines (Ruth Karron)Accelerating Vaccine Development (Deborah Higgins)Interactive round table discussion with the speakers
10:45 – 11:30 Coffee/Tea break & Posters
Session III RSV ANTIBODIES, ARE THEY THE MAIN SURROGATE OF PROTECTION?
11:30 – 11:4511:45 – 12:0512:05 – 12:2512:25 – 12:4512:45 – 13:00
Session introduction, identifying gaps and aims of session (Chair: Helen Chu/Pedro Piedra) Transplacental antibody transfer, does time matters? (Helen Chu)Is it pre F, post F or G? (Jose Melero)What is the threshold of protection? (Pedro Piedra)Interactive round table discussion with the speakers
13:00 – 14:30 Lunch
Session IV RSV IN VULNERABLE POPULATIONS
14:30 – 14:4014:40 – 15:0015:00 – 15:2015:20 – 15:40
15:40 – 15:50
Session introduction, identifying gaps and aims of session (Chair: Janet Englund/Octavio Ramilo)RSV burden in preterm infants (Anne Greenough) RSV in immunocompromised patients (Jan Englund)Human volunteer challenge and RSV vaccines for adults: what role could there be? (Peter Openshaw)Interactive round table discussion with the speakers
15:50 – 16:40 Coffee/Tea break & Posters
Session V RSV SURVEILLANCE AND GUIDELINES
16:40 – 16:50
16:50 – 17:10
17:10 – 17:30
17:30 – 17:5017:50 – 18:1018:10 – 18:30
18:30 – 18:4518:45 – 19:45
Session introduction, identifying gaps and aims of session (Chair: Asuncion Meijas/Eugenio Baraldi)Guideline on the clinical evaluation of medicinal products indicated for the prophylaxis or treatment of RSV disease (Mair Powell, EMA)WHO Guidelines and international standards for regulatory evaluation of RSV vaccines and mabs (Ivana Knezevic)RSV surveillance in the United States (Susan Gerber, CDC)RSV Vaccines for antimicrobial resistance (Niteen Wairagkar, BMGF)Introduction of WHO RSV surveillance strategy and update on the surveillance pilot (Siddhivinayak Hirve, WHO)Interactive round table discussion with the speakers YOUNG RESEARCHERS EXPERT WORKSHOP (only for young researchers to attend)
20:00 – 23:00 Dinner
PROGRAM | DAY 2 THURSDAY 30 NOVEMBER
PROGRAM | DAY 3 FRIDAY 1 DECEMBER
Session VI STATUS OF VACCINE DEVELOPMENTS
08:30 – 08:35
08:35 – 09:00
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
Session introduction, identifying gaps and aims of session (Chair: Ann Falsey/Ed Walsh)
History and future of RSV vaccines (Ed Walsh)
RSV G protein as an antibody and vaccine target (Larry Kauvar, Trellis Biosciences)
Safety, immunogenicity and efficacy of a molecularly adjuvanted adenovirus 5-based RSV vaccine
in cotton rats (Roberto Mateo, Vaxart Inc.)
MEDI8897, an extended half-life RSV neutralizing monoclonal antibody (Anis Khan, MedImmune)
09:45 – 10:00
10:00 – 11:00
Coffee/Tea break
Poster walk
Session VI
part 2
STATUS OF VACCINE DEVELOPMENTS
11:15 – 11:30
11:30 – 11:45
11:45 – 12:00
12:00 – 12:15
(Chair: Ann Falsey/ Ed Walsh)
A phase II safety and immunogenicity trial of RSV f vaccine in adults ≥ 60 years (Novavax)
Safety and immunogenicity of a phase 1 study in older adults (Benoit Callendret, Janssen)
Confirmed safety and broad immunogenicity of MVA BN RSV vaccine in ≥ 55 year old adults
(Nathaly Samy, Bavarian Nordic)
Interactive round table discussion with the speakers
Session VII SURROGATE MARKERS OF VACCINE EFFICACY: SEROLOGY AND BEYOND
12:15 – 12:20
12:20 – 12:40
12:40 – 13:00
13:00 – 13:20
13:20 – 13:30
Session introduction, identifying gaps and aims of session (Chair: Peter Openshaw /Marta Nunes)
Predictors to immune responses to vaccination in young infants (Octavio Ramilo)
Clinical endpoints in trials of RSV vaccines in pregnant women: study design issues, assessment
of safety and effectiveness (Marta Nunes)
Immune response to vaccines in the older adults (Ann Falsey)
Round Table Discussion with the speakers
13:30 – 14:30 Lunch
Session VIII RSV AND LONG-TERM SEQUELAE
14:30 – 14:40
14:40 – 15:00
15:00 – 15:20
15:20 – 15:40
15:40 – 16:00
16:00 – 16:15
16:15 – 16:25
16:25 – 16:45
Session introduction, identifying gaps and aims of session (Chair: Louis Bont /Renato Stein)
The epidemiological link between RSV and asthma (Tina Hartert)
Lessons learned from Immunoprophylaxis RCTs (Eric Simoes)
Follow-up in RSV Vaccine Trials: how long is enough? (Louis Bont)
Interactive round table discussion with the speakers
Announcement Winner Young Researchers Tournament (Natalie Mazur/Barney Graham)
Wrapping up meeting (Asuncion Mejias & Jan Asun)
Closing Remarks by ReSViNET (Louis Bont and Leyla Kragten)
LOCATION
The conference will take place in theSpanish city Málaga.
Málaga is a city on the Mediterranean inSouth Spain and the heart of the Costa delSol. The vibrant cosmopolitan city of Málagais situated on the beautiful Andalucíacoastline. Blessed with sunshine, Málagaprovides lively nightlife, museums andexceptional seafood restaurants alongsidewide boulevards, swaying palm trees andbeautiful beaches.
Guests can enjoy the beautiful and quietseaside, visit the Picasso museum andPicasso’s birth house, walk through thesmall and picturesque streets in the historiccentre and have the possibility to encounterAntonio Banderas, who is the pride of thecity.
LOCATION & ACCOMODATION
RSV Vaccines for the World 2017 will be heldin the heart of the Spanish city Málaga, inCine Albéniz.
Cine Albéniz is an old characteristic cinemawhich is located in the historic centre ofMálaga next to the roman theatre whichwas built in the 1st century AD and theAlcabaza castle which was built in order toprotect the city from its enemies.
We would like to recommend the AC Hotel Malaga Palacio. From the conference center it takes 3 minutes by foot to arrive at AC Hotel Malaga Palacio. The hotel is located in the center of a shopping area, in the vicinity of Museo Automovilistico De Malaga, Museum of Malaga and Malagueta Beach.
RSVVW ‘17 does not have an arrangement with AC Hotel Malaga Palacio, bookings can be made through their website.
Address: Address:AC Malaga Palacio Hotel Cine AlbénizCortina Del Muelle, 1 Alcazabilla, 429015, Malaga, 29015, MálagaSpain Spain
PARTICIPANT REGULAR FEE(PAYMENT RECEIVED BY 31 OCT.)
LATE FEE(PAYMENT RECEIVED AFTER 1ST OF NOV.)
BENEFITS LINKED TO THE REGISTRATION FEE
Full Participants € 750 € 880 • Attendance to all scientific sessions• Poster sessions• Invitation to the Opening Reception• Refreshments during the meeting and
lunch • Dinner and networking on 30th of
November • Congress material
(PhD) Students, Fellows and Trainees
€ 295 € 365 • Attendance to all scientific sessions • Poster sessions• Activities young researchers
(presentation tournament &masterclass)
• Invitation to the Opening Reception• Refreshments during the meeting and
lunch • Dinner and networking on 30th of
November • Congress material
REGISTRATION & FEES
ACKNOWLEDGEMENTS
Platinum Supporters*
Gold Supporters*
Silver Supporters
*Limited availability
The Organising Committee and the Board of ReSViNET would like to express gratitude andacknowledge the following companies and institutes for their generous support of the RSVVaccines for the World conference 2017, organised by ReSViNET.
Bronze Supporters
ReSViNET
ReSViNET is an international network of clinician
scientists with an integrated, multidisciplinary and
translational research approach focused on RSV
infection. ReSViNET is stimulating and performing
research aiming to understand the burden of RSV
infection, to advocate for better care for patients
with RSV infection and to provide effective
partnerships with relevant stakeholders.
ReSViNET Annual Meetings are devoted
exclusively to RSV infection prevention and
treatment and is focusing on the scientific
developments and demands in RSV field.
We aim to bring together the scientific data and
expertise, connecting different stakeholders
involved in RSV research e.g. Scientists, policy
makers and Pharmaceutical companies and
stimulating discussions regarding the
opportunities for future international
collaboration and achievement in our field.
WHY JOIN US?
• CONTINUE FOCUSING ON DEVELOPING RSV THERAPIES AND VACCINES
•REACH ACADEMIC LEADERS AND TOP SCIENTISTS IN THE FIELD
•NETWORKING WHILE WORKING
• CUTTING-EDGESCIENTIFIC RESEARCH
•OPPORTUNITIES FOR FUTURE INTERNATIONAL COLLABORATION
We look forward in welcoming you to Málaga between November 29th to December 1st for the RSV Vaccines for the World conference organised by ReSViNET.
If you have any questions or require additional information, please contact:
Leyla Kragten-Tabatabaie, PhDReSViNET Scientific Network Managert +31 (0)6 11331391e [email protected] [email protected] w www.resvinet.org
